Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

scientific article

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2967/JNUMED.115.154138
P698PubMed publication ID25883123

P50authorMatthieu Resche-RigonQ41907674
Elif HindiéQ47460841
Dimitris VisvikisQ91680418
P2093author name stringAnne de Roquancourt
Marc Espié
Alice Sanna
Patricia de Cremoux
Sylvie Giacchetti
Luis Teixeira
David Groheux
Pascal Merlet
Mathieu Hatt
Mohamed Majdoub
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectchemotherapyQ974135
P304page(s)824-831
P577publication date2015-04-16
P1433published inThe Journal of Nuclear MedicineQ7743608
P1476titleBaseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
P478volume56

Reverse relations

cites work (P2860)
Q5258434018FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
Q3756658018FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis
Q38726440Biomarkers of residual disease after neoadjuvant therapy for breast cancer
Q38663416Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
Q43082312Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Q53396296Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.
Q48047542Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients
Q58775208Early metabolic 18F-FDG PET/CT response of locally advanced squamous-cell carcinoma of head and neck to induction chemotherapy: A prospective pilot study
Q36403339Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy
Q55505363FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.
Q50172829Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy
Q51727954Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?
Q90260579PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues
Q92807885Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
Q52895573The Role of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors.
Q41491212Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
Q37582345¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer
Q38693888¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials

Search more.